The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.

What Is The Investigation About?
On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company’s Chief Executive Officer, Ronald Kurtz, disclosed that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.”

On this news, RxSight’s stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume.